Profound Medical Corp.
PROF · XNASCIK 1628808fmd_0T6WYD9XAWF9GRYPYXK45M1SKTManufacturing · Surgical & Medical Instruments & ApparatusTemplate: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 17 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 4 | 7 | 7 | 7 | 7 | 11 | 16 |
| Rental revenue | – | – | – | – | 1 | 1 | – |
| Cost of revenue | 2 | 4 | 4 | 4 | 3 | 4 | 5 |
| Gross profit | 2 | 3 | 3 | 3 | 4 | 7 | 11 |
| Research and development | 9 | 10 | 15 | 15 | 14 | 17 | 21 |
| Selling, general and administrative | 8 | 12 | 18 | 18 | 19 | 23 | 32 |
| Total operating expenses | – | – | – | – | 33 | 40 | 53 |
| Operating income | (15) | (19) | (30) | (32) | (29) | (33) | (41) |
| Interest expense | 0 | 3 | 0 | 0 | 0 | 1 | 0 |
| Other non-operating income (expense) | – | – | – | – | 0 | 5 | (1) |
| Income before taxes | (15) | (22) | (31) | (28) | (28) | (28) | (42) |
| Income tax expense | 0 | 0 | 0 | 0 | (0) | (0) | 0 |
| Net income from continuing operations | (15) | (22) | (31) | (29) | (28) | (28) | (43) |
| Net income | (15) | (22) | (31) | (29) | (28) | (28) | (43) |
| Net income to common shareholders | – | – | – | – | – | 28 | 43 |